Stifel Financial Corp Has $191,000 Stake in Precision BioSciences, Inc. (NASDAQ:DTIL)

Stifel Financial Corp lowered its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 30.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,270 shares of the company’s stock after selling 9,185 shares during the quarter. Stifel Financial Corp owned about 0.28% of Precision BioSciences worth $191,000 at the end of the most recent reporting period.

Separately, Janus Henderson Group PLC lifted its position in shares of Precision BioSciences by 10.9% during the 3rd quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after acquiring an additional 68,943 shares during the period. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Stock Performance

Shares of Precision BioSciences stock opened at $4.26 on Tuesday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences, Inc. has a 1-year low of $4.13 and a 1-year high of $19.43. The company has a market cap of $32.68 million, a PE ratio of 71.01 and a beta of 1.41. The company has a 50 day moving average of $6.79 and a 200-day moving average of $8.60.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.